EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitSystematische ÜbersichtOpen Access · CC BY 4.0

Glucagon-like Peptide-1 Receptor Agonists and Alcohol Use Outcomes: A Systematic Review of Clinical Evidence

Ibrahim K Altami, Eyad A Alabdulrahim iD, Osamah M Alfayez iD

Journal of Clinical Medicine · 19.06.2026 · 15 (12) · 4781

DOI: 10.3390/jcm15124781 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 19.06.2026. Verfasst von Ibrahim K Altami und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy Practice, College of Pharmacy, Qassim University, Buraydah 52571, Saudi Arabia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for type 2 diabetes and obesity treatment and may influence reward-related behaviors, including alcohol use. This study aimed to evaluate the effects of GLP-1RAs on alcohol consumption and related outcomes in adults with alcohol use or alcohol use disorder (AUD).

Methods

A systematic review was conducted following PRISMA 2020 guidelines. PubMed and Web of Science were searched from inception to December 2025. Eligible studies included randomized controlled trials (RCTs), secondary analyses of RCTs, and observational studies reporting quantitative alcohol consumption outcomes. Data extraction and risk of bias assessment (RoB 2 and ROBINS-I) were performed independently by two reviewers.

Results

Five studies (n = 49,892) were included, comprising three RCT-based analyses and one large cohort study. Semaglutide and dulaglutide were associated with modest reductions in alcohol consumption and craving in several studies, with statistically significant improvements in selected behavioral outcomes. In contrast, exenatide did not demonstrate significant effects in the overall AUD population, with signals limited to subgroups. The cohort study showed small but statistically significant reductions in AUDIT-C scores following GLP-1RA initiation. Objective measures (e.g., PEth, breath alcohol concentration) showed reductions in selected contexts but were reported in a few studies.

Conclusions

GLP-1RAs may be associated with modest reductions in alcohol consumption, but evidence remains limited and heterogeneous. Larger, well-designed RCTs are needed to define their role in the management of AUD.

Schlagwörter

Stichwörter der Autor:innen

GLP-1 receptor agonistsalcohol consumptionalcohol use disorderdulaglutidesemaglutidesystematic review

Autor:innen und Institutionen

  • Department of Pharmacy Practice, College of Pharmacy, Qassim University, Buraydah 52571, Saudi Arabia.

ORCID-Profile: Eyad A Alabdulrahim, Osamah M Alfayez

Zitieren

APA

Altami, I. K., Alabdulrahim, E. A., & Alfayez, O. M. (2026). Glucagon-like Peptide-1 Receptor Agonists and Alcohol Use Outcomes: A Systematic Review of Clinical Evidence. Journal of Clinical Medicine, 15(12), 4781. https://doi.org/10.3390/jcm15124781

Vancouver

Altami IK, Alabdulrahim EA, Alfayez OM. Glucagon-like Peptide-1 Receptor Agonists and Alcohol Use Outcomes: A Systematic Review of Clinical Evidence. Journal of Clinical Medicine. 2026;15(12):4781. doi:10.3390/jcm15124781

BibTeX
@article{Altami2026,
  author = {Altami, Ibrahim K and Alabdulrahim, Eyad A and Alfayez, Osamah M},
  title = {Glucagon-like Peptide-1 Receptor Agonists and Alcohol Use Outcomes: A Systematic Review of Clinical Evidence},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {12},
  pages = {4781},
  doi = {10.3390/jcm15124781}
}
Kostenlos starten →